Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cipla
Chubb
Merck
Queensland Health
Teva
Baxter
Argus Health
Mallinckrodt
Daiichi Sankyo
Healthtrust

Generated: January 23, 2018

DrugPatentWatch Database Preview

Teva Pharms Usa Company Profile

« Back to Dashboard

What is the competitive landscape for TEVA PHARMS USA, and what generic alternatives to TEVA PHARMS USA drugs are available?

TEVA PHARMS USA has one hundred and forty-four approved drugs.

There are five US patents protecting TEVA PHARMS USA drugs on TEVA PHARMS USA drugs in the past three years. There are nineteen tentative approvals on TEVA PHARMS USA drugs.

There are fifty-four patent family members on TEVA PHARMS USA drugs in thirty-one countries and two hundred and ninety-eight supplementary protection certificates in thirteen countries.

Summary for Teva Pharms Usa
International Patents:54
US Patents:5
Tradenames:124
Ingredients:122
NDAs:144

Drugs and US Patents for Teva Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharms Usa EZETIMIBE ezetimibe TABLET;ORAL 078724-001 Jun 12, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa ATOMOXETINE HYDROCHLORIDE atomoxetine hydrochloride CAPSULE;ORAL 079022-002 May 30, 2017 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa URSODIOL ursodiol TABLET;ORAL 079184-001 May 13, 2009 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa PANCURONIUM BROMIDE pancuronium bromide INJECTABLE;INJECTION 072759-001 Jul 31, 1990 AP RX No Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa AMLODIPINE AND OLMESARTAN MEDOXOMIL amlodipine besylate; olmesartan medoxomil TABLET;ORAL 091154-004 Oct 26, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa ENTECAVIR entecavir TABLET;ORAL 202122-002 Aug 26, 2014 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa PIOGLITAZONE HYDROCHLORIDE pioglitazone hydrochloride TABLET;ORAL 077210-003 Jan 10, 2014 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE buprenorphine hydrochloride; naloxone hydrochloride TABLET;SUBLINGUAL 091149-001 Sep 8, 2014 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa DOCETAXEL docetaxel INJECTABLE;INJECTION 203877-001 Sep 16, 2015 AP RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Teva Pharms Usa PARICALCITOL paricalcitol CAPSULE;ORAL 090829-001 Sep 27, 2013 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Teva Pharms Usa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-003 Jan 28, 2014 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate FOR SOLUTION;SUBCUTANEOUS 020622-001 Dec 20, 1996 ➤ Subscribe ➤ Subscribe
Teva Pharms Usa COPAXONE glatiramer acetate INJECTABLE;SUBCUTANEOUS 020622-002 Feb 12, 2002 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TEVA PHARMS USA drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 6/3/2015
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 2/26/2014
➤ Subscribe Injection 40 mg/mL, 1 mL pre-filled syringe ➤ Subscribe 1/29/2014

International Patents for Teva Pharms Usa Drugs

Supplementary Protection Certificates for Teva Pharms Usa Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2016000024 Germany ➤ Subscribe PRODUCT NAME: TENOFOVIRALAFENAMID ODER EIN SALZ ODER SOLVAT DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119
2016000104 Germany ➤ Subscribe PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON UND TENOFOVIRALAFENAMID ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, INSBESONDERE TENOFOVIRALAFENAMIDFUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 20151119
/2001 Austria ➤ Subscribe PRODUCT NAME: ELETRIPTAN UND DIE PHARMAZEUTISCH VERTRAEGLICHEN SALZE DAVON, EINSCHLIESSLICH DES HYDROBROMIDS; NAT. REGISTRATION NO/DATE: 1-24155 20010801; FIRST REGISTRATION: LI 55218 01, 55218 02 20001214
/2016 Austria ➤ Subscribe PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND TENOFOVIR ALAFENAMID ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE TENOFOVIR ALAFENAMID FUMARAT; REGISTRATION NO/DATE: EU/1/15/1061 (MITTEILUNG) 20151123
1999 Austria ➤ Subscribe PRODUCT NAME: FOSPHENYTOIN-NATRIUM; NAT. REGISTRATION NO/DATE: 1-22664 19980728; FIRST REGISTRATION: GB 00019/0157 19980204
/2015 Austria ➤ Subscribe PRODUCT NAME: ETHINYLESTRADIOL UND EINE KOMBINATION VON LEVONORGESTREL UND ETHINYLESTRADIOL; NAT. REGISTRATION NO/DATE: 136021 20150224; FIRST REGISTRATION: SK 17/0017/15-S 20150211
2014 00048 Denmark ➤ Subscribe PRODUCT NAME: KOMBINATION AF ROSUVASTATIN OG EZETIMIBE ELLER FARMACEUTISK ACCEPTABLE SALTE DERAF, HERUNDER ROSUVASTATIN SOM ZINK; NAT. REG. NO/DATE: 52921, 52922, 52923 20140820; FIRST REG. NO/DATE: NO 13-9663, 13-9664, 13-9665 20140724
C0025 Belgium ➤ Subscribe PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215
2015 00055 Denmark ➤ Subscribe PRODUCT NAME: KOMBINATION AF RILPIVIRIN ELLER EN TERAPEUTISK AEKVIVALENT FORM DERAF, SOM ER BESKYTTET AF GRUNDPATENTET, SASOM ET FARMECEUTISK ACCEPTABELT SALT AF RILPIVIRIN, HERUNDER HYDROCHLORIDSALTET AF RILPIVIRIN, TENOFOVIR, NAVNLIG TENOFOVIRDISOPROXILFUMARAT; REG. NO/DATE: EU/1/11/737/001-002 20111128
0669 Netherlands ➤ Subscribe PRODUCT NAME: ARIPIPRAZOLE; REGISTRATION NO/DATE: EU/1/13/882 20131115
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Merck
UBS
Deloitte
QuintilesIMS
Chubb
McKesson
Healthtrust
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot